Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer

Journal of the Egyptian National Cancer Institute

Volumn 25, Issue 1, 2013, Pages 51-56

  Elsabah, Mahmoud Tag ^a   Adel, Iman ^b  

^a Misr University for Science and Technology   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

EGFR targeted monoclonal antibody; Immunohistochemistry; K ras protein; Metastatic colorectal cancer

Indexed keywords

K RAS PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLOID CARCINOMA; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; ONCOGENE K RAS; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 84875095156     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2013.01.003     Document Type: Article

References (27)

1. Mokhtar N.M., Gouda I., Adel I. Cancer pathology registry (2003-2004) and time trend analysis 2007, Department of Pathology, National Cancer Institute Cairo University, p. 14-56.
2. Afify M., Samy N., Hashim M., Essam T. Clinical significance of vascular endothelial growth factor in Egyptian colorectal cancer patients. Int J Integr Biol 2008, 4(2):100-107.
3. Strimpakos A.S., Syrigos K.N., Saif M.W. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J 2009, 9:147-160.
4. Tamer F., Taha A. Usefulness of PET-CT in the assessment of suspected recurrent colorectal carcinoma. Egypt J Radiol Nucl Med 2012, 43(2):129-137.
5. Cejas P., López-Gómez M., Aguayo C., Madero R., De Castro Carpeño J., Belda-Iniesta C., et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009, 4(12):e8199.
6. Mokhtar N.M. Oncogenes and tumor suppressor genes. Molecular pathology of cancer 1998, 82-84. The National Cancer Institute, Cairo University, Cairo.
7. Akkiprik M., Celikel C.A., Dusunceli F., Sonmez O., Gulluoqlu B.M., Sav A., et al. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. Turk J Gastroenterol 2008, 19:22-27.
8. Malumbres M., Barbacid M. RAS oncogenes: the first 30years. Nat Rev Cancer 2003, 3:459-465.
9. Kislitsin D., Lerner A., Rennert G., Lev Z. K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig Dis Sci 2002, 47:1073-1079.
10. Jančík S., Drábek J., Radzioch D., Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010, 2010:150960.
11. Liu X., Jakubowski M., Hunt J.L. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 2011, 135:245-252.
12. Goodsell D.S. The molecular perspective: epidermal growth factor. Oncologist 2003, 8(5):496-497.
13. Milano G., Etienne-Grimaldi M., Dahan L., Francoual M., Spano J., Benchimol D., et al. Epidermal growth factor receptor (EGFR) status and K-ras mutations in colorectal cancer. Ann Oncol 2008, 19(12):2033-2038.
14. Spano J., Lagorce C., Atlan D., Milano G., Domont J., Benamouzig R., et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005, 16(1):102-108.
15. Krasinskas AM. EGFR signaling in colorectal carcinoma. Pathol Res Int 2011;2011.. doi:10.4061/2011/932932.
16. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor - targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324.
17. Dahabreh I.J., Terasawa T., Castaldi P.J., Trikalinos T.A. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Int Med 2011, 154:37-49.
18. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
19. Wang H.L., Lopategui J., Amin M.B., Patterson S.D. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010, 17(1):23-32.
20. Chustecka Z. KRAS mutation predicts lack of response to EGFR inhibitors. Medscape medical news: 14th European cancer conference 2007. Available from http://www.medscape.com/viewarticle/563710.
21. Bohanes P., LaBonte M.J., Winder T., Lenz H.J. Predictive molecular classifiers in colorectal cancer. Semin Oncol 2011, 38(4):576-587.
22. Pan Z.Z., Wan D.S., Chen G., Li L.R., Lu Z.H., Huang B.J. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World J Gastroenterol 2004, 10(24):3688-3690.
23. Jönsson M., Ekstrand A., Edekling T., Eberhard J., Grabau D., Borg D., Nilbert M. Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clin Pathol 2009, 9:8.
24. Sammoud S., Khiari M., Semeh A., Amine L., Ines C., Amira A., et al. Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Appl Immunohistochem Mol Morphol 2012, 20(2):146-152.
25. Bedeir A., Krasinskas A.M. Molecular diagnosis of colorectal cancer. Arch Pathol Lab Med 2011, 135(5):578-587.
26. Schimanski C.C., Linnemann U., Berger M.R. Sensitive detection of K-ras mutation augments diagnosis of colorectal cancer metastases in the liver. J Cancer Res 2009, 59:5169-5175.
27. Okulczyk B., Kovalchuk O., Piotrowski Z., Mysliwiec P., Chyczewski L. Clinical usefulness of K-RAS mutation detection in colorectal cancer and in surgical margins of the colon. Rocz Acad Med Bialymst 2004, 49(Suppl. 1):52-54.